Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
-Medical News
 Blood Safety News
 NHF and Community News
 Industry News
 Travel Advisory

 

 

 
Hepatitis C Treatment Study Open to Latino and Caucasian Patients
 

Medical centers across the U.S. are recruiting Hispanic and Non-Hispanic Caucasian patients for a new hepatitis C treatment study. The Hepatitis C Latino Study will assess response to standard interferon/ribavirin treatment in Latino patients versus non-Latino Caucasian patients with chronic hepatitis C. The study will measure the efficacy and safety of the combination therapy in patients. Over the course of 48 weeks, researchers will examine data gathered from over 500 study participants, to help determine whether there is a significant connection between race and effectiveness of the treatment. 

 

The study is sponsored by the research and pharmaceutical company Hoffmann-La Roche. Approximately 60 medical centers in California, Florida, New York, Texas and several other states are currently enrolling patients. Eligibility criteria, study locations and other information can be found at www.clinicaltrials.gov/ct/gui/show/NCT00107653 or by calling 800-526-6367.

 

This section of our Web site is sponsored by: